CNS Drugs

, Volume 23, Issue 12, pp 1003–1021

Adverse Endocrine and Metabolic Effects of Psychotropic Drugs

Selective Clinical Review
  • Chaya G. Bhuvaneswar
  • Ross J. Baldessarini
  • Veronica L. Harsh
  • Jonathan E. Alpert
Review Article

Abstract

The article critically reviews selected, clinically significant, adverse endocrine and metabolic effects associated with psychotropic drug treatments, including hyperprolactinaemia, hyponatraemia, diabetes insipidus, hypothyroidism, hyperparathyroidism, sexual dysfunction and virilization, weight loss, weight gain and metabolic syndrome (type 2 diabetes mellitus, dyslipidaemia and hypertension). Such effects are prevalent and complex, but can be managed clinically when recognized. They encourage continued critical assessment of benefits versus risks of psychotropic drugs and underscore the importance of close coordination of psychiatric and general medical care to improve long-term health of psychiatric patients. Options for management of hyperprolactinaemia include lowering doses, switching to agents such as aripiprazole, clozapine or quetiapine, managing associated osteoporosis, carefully considering the use of dopamine receptor agonists and ruling out stress, oral contraceptive use and hypothyroidism as contributing factors. Disorders of water homeostasis may include syndrome of inappropriate antidiuretic hormone (SIADH), managed by water restriction or slow replacement by hypertonic saline along with drug discontinuation. Safe management of diabetes insipidus, commonly associated with lithium, involves switching mood stabilizer and consideration of potassium-sparing diuretics. Clinical hypothyroidism may be a more useful marker than absolute cut-offs of hormone values, and may be associated with quetiapine, antidepressant and lithium use, and managed by thyroxine replacement. Hyper-parathyroidism requires comprehensive medical evaluation for occult tumours. Hypocalcaemia, along with multiple other psychiatric and medical causes, may result in decreased bone density and require evaluation and management. Strategies for reducing sexual dysfunction with psychotropics remain largely unsatisfactory. Finally, management strategies for obesity and metabolic syndrome are reviewed in light of the recent expert guidelines, including risk assessment and treatments, such as monoamine transport inhibitors, anticonvulsants and cannabinoid receptor antagonists, as well as lifestyle changes.

Supplementary material

40263_2012_23121003_MOESM1_ESM.pdf (16 kb)
Supplementary material, approximately 16 KB.

References

  1. 1.
    Larsen PR, Kronenberg HM, Melmed S, et al., editors. Williams textbook of endocrinology. 10th ed. Philadelphia (PA): Saunders, 2003Google Scholar
  2. 2.
    Polishuk WZ, Kulcsar S. Effects of chlorpromazine on pituitary function. J Clin Endocrinol Metab 1956; 16: 292–3PubMedCrossRefGoogle Scholar
  3. 3.
    Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences: selective literature review. Br J Psychiatry 2003; 182: 199–204PubMedCrossRefGoogle Scholar
  4. 4.
    Bushe C, Shaw M. Prevalence of hyperprolactinemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical anti-psychotics. J Psychopharmacol 2007; 21: 768–9PubMedCrossRefGoogle Scholar
  5. 5.
    Langer G, Sachar EJ, Nathan RS, et al. Dopaminergic factors in human prolactin regulation: a pituitary model for the study of a neuroendocrine system in man. Psychopharmacology 1979; 65: 161–4PubMedCrossRefGoogle Scholar
  6. 6.
    Fowlie S, Burton J. Hyperprolactinaemia and nonpuerperal lactation associated with clomipramine. Scott Med J 1987; 32: 52–3PubMedGoogle Scholar
  7. 7.
    Barbaro D, Faggionato F, Pallini S, et al. Verapamil acute administration: a new dynamic test in hyperprolactinemic states. Metabolism 1999; 48: 1351–6PubMedCrossRefGoogle Scholar
  8. 8.
    Ziambaras K, Dagogo-Jack S. Tumor-grade hyperprolactinemia induced by multiple medications in the setting of renal failure. Endocrinol Pract 1999; 5: 139–42Google Scholar
  9. 9.
    Molitch ME. Disorders of prolactin secretion. Endocrinol Metab Clin North Am 2001; 30: 586–610CrossRefGoogle Scholar
  10. 10.
    Orlando G, Brunetti L, Vacca M. Ritonavir and saquinavir directly stimulate anterior pituitary prolactin secretion, in vitro. Int J Immunopathol Pharmacol 2002; 15: 65–8PubMedGoogle Scholar
  11. 11.
    Papakostas GI, Miller KK, Petersen T, et al. Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluox-etine. J Clin Psychiatry 2006; 67: 952–7PubMedCrossRefGoogle Scholar
  12. 12.
    Monteleone P, Maj M, Ariano MG, et al. Prolactin response to sodium valproate in schizophrenics with and without tardive dyskinesia. Psychopharmacology 1988; 96: 223–6PubMedCrossRefGoogle Scholar
  13. 13.
    Isojärve JI, Pakarinen AJ, Myllylä VV. Effects of carbamazepine on the hypothalamic-pituitary-gonadal axis in male patients with epilepsy: prospective study. Epilepsia 1989; 30: 446–52CrossRefGoogle Scholar
  14. 14.
    Marken PA, Haykal RF, Fisher JN. Management of psychotropic-induced hyperprolactinemia. Clin Pharm 1992; 11: 851–6PubMedGoogle Scholar
  15. 15.
    Hirschfeld RM. Management of sexual side effects of antidepressant therapy. J Clin Psychiatry 1999; 60Suppl. 14: 27–35PubMedGoogle Scholar
  16. 16.
    El Khoury A, Tham A, Mathe AA, et al. Decreased plasma prolactin release in euthymic lithium-treated women with bipolar disorder. Neuropsychobiology 2003; 48: 14–8PubMedCrossRefGoogle Scholar
  17. 17.
    Van Cauter E, Linkowski P, Kerkhofs M, et al. Circadian and sleep-related endocrine rhythms in schizophrenia. Arch Gen Psychiatry 1991; 48: 348–56PubMedCrossRefGoogle Scholar
  18. 18.
    Kopacek M, Bares M, Svarc J, et al. Hyperprolactinemia after low dose of amisulpride. Neuroendocrinol Lett 2004; 25: 419–22Google Scholar
  19. 19.
    Paparrigopoulos T, Liappas J, Tzavellas E, et al. Amisulpride-induced hyperprolactinemia is reversible following discontinuation. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 92–6PubMedCrossRefGoogle Scholar
  20. 20.
    Chouinard G, Annable L, Campbell W. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. J Clin Psychopharmacol 1989; 9: 247–53PubMedCrossRefGoogle Scholar
  21. 21.
    Melkersson KI. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum Psychopharmacol 2006; 21: 529–32PubMedCrossRefGoogle Scholar
  22. 22.
    Lai YC, Chou CC, Chen CH, et al. Significant elevations of prolactin levels in patients who shifted from conventional depot antipsychotics to long-acting risperidone. J Clin Psychopharmacol 2007; 27: 523–4PubMedCrossRefGoogle Scholar
  23. 23.
    Maguire GA. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 2002; 63 Suppl. 4: 56–62Google Scholar
  24. 24.
    Baldessarini RJ, Tarazi FI. Chapter 18: pharmacotherapy of psychosis and mania. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 1 1th ed. New York: McGraw-Hill Press, 2005: 461–500Google Scholar
  25. 25.
    Costa AM, de Lima MS, Faria M. Naturalistic, ninemonth follow-up, comparing olanzapine and conventional antipsychotics on sexual function and hormonal profile for males with schizophrenia. J Psychopharmacol 2007; 21: 165–70PubMedCrossRefGoogle Scholar
  26. 26.
    Saldana SN, Delgado SV. Ziprasidone-associated galactorrhea in an adolescent female. J Child Adolesc Psychopharmacol 2007; 17: 259–60PubMedCrossRefGoogle Scholar
  27. 27.
    Kim KS, Pae CU, Chae JH, et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry 2002; 63: 408–13PubMedCrossRefGoogle Scholar
  28. 28.
    Wahl R, Ostroff R. Reversal of symptomatic hyperprolactinemia by aripiprazole. Am J Psychiatry 2005; 162: 1542–3PubMedCrossRefGoogle Scholar
  29. 29.
    Shim JC, Shin JG, Kelly DL. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychoticinduced hyperprolactinemia: placebo-controlled trial. Am J Psychiatry 2007; 164: 1404–10PubMedCrossRefGoogle Scholar
  30. 30.
    Wolf J, Fiedler U. Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole. J Clin Pharm Ther 2007; 32: 197–8PubMedCrossRefGoogle Scholar
  31. 31.
    Molitch M. Medication-induced hyperprolactinemia. Mayo Clin Proc 2005; 80: 1050–7PubMedCrossRefGoogle Scholar
  32. 32.
    Staller J. Effect of long-term antipsychotic treatment on prolactin. J Child Adolesc Psychopharmacol 2006; 16: 317–26PubMedCrossRefGoogle Scholar
  33. 33.
    Brown WA, Laughren TP. Tolerance to the prolactinelevating effects of neuroleptics. Psychiatry Res 1981; 5: 317–22PubMedCrossRefGoogle Scholar
  34. 34.
    Kinon BJ, Gilmore JA, Liu H, et al. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology 2003; 28: 55–68PubMedCrossRefGoogle Scholar
  35. 35.
    Alpert M, Diamond F, Kesselman M. Correlation between extrapyramidal and therapeutic effects of neuroleptics. Compr Psychiatry 1977; 18: 333–6PubMedCrossRefGoogle Scholar
  36. 36.
    McEvoy JP. The neuroleptic threshold as a marker of minimum effective neuroleptic dose. Compr Psychiatry 1986; 27: 327–35PubMedCrossRefGoogle Scholar
  37. 37.
    Stevens JR, Kysmissis PI, Baker AJ. Elevated prolactin levels in male youths treated with risperidone and quetiapine. J Child Adolesc Psychopharmacol 2005; 15: 893–900PubMedCrossRefGoogle Scholar
  38. 38.
    Holzer M, Eap CB. Risperidone-induced symptomatic hyperprolactinaemia in adolescents. J Clin Psychopharmacol 2006; 26: 167–71PubMedCrossRefGoogle Scholar
  39. 39.
    Lee BH, Kim YK. Relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 658–62PubMedCrossRefGoogle Scholar
  40. 40.
    Misra M, Papakostas GI, Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 2004; 65: 1607–18PubMedCrossRefGoogle Scholar
  41. 41.
    Romeo JH, Ybarra J. Hypogonadal hypogonadism and osteoporosis in men. Nurs Clin No Am 2007; 42: 87–99CrossRefGoogle Scholar
  42. 42.
    Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004; 64: 2291–314PubMedCrossRefGoogle Scholar
  43. 43.
    Thangavelu K, Geetanjali S. Menstrual disturbance and galactorrhea in people taking conventional antipsychotic medications. Exp Clin Psychopharmacol 2006; 14: 459–60PubMedCrossRefGoogle Scholar
  44. 44.
    Prabhakar VK, Davis JR. Hyperprolactinaemia. Best Pract Res Clin Obstet Gynaecol 2008; 22: 341–53PubMedCrossRefGoogle Scholar
  45. 45.
    Loh C, Leckband SG, Meyer JM. Risperidone-induced retrograde ejaculation: case report and review of the literature. Int Clin Psychopharmacol 2004; 19: 111–2PubMedCrossRefGoogle Scholar
  46. 46.
    Aleem M, Choudhari J, Padwal V. Hyperprolactinemia affects spermiogenesis in adult male rats. J Endocrinol Invest 2005; 28: 39–48PubMedGoogle Scholar
  47. 47.
    Giagulli VA, Carbone D. Hormonal control of inhibin-B in men. J Endocrinol Invest 2006; 29: 706–13PubMedGoogle Scholar
  48. 48.
    Whalley LJ, Christie JE, Blackwood DH, et al. Disturbed endocrine function in the psychoses: disordered homeostasis or disease process? Br J Psychiatry 1989; 155: 455–61PubMedCrossRefGoogle Scholar
  49. 49.
    Harvey PW, Everett DJ, Springall CJ. Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: role in breast and prostate cancer. Hum Exp Toxicol 2006; 25: 395–404PubMedCrossRefGoogle Scholar
  50. 50.
    Szarfman A, Tonning JM, Levine JG, et al. Atypical anti-psychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy 2006; 26: 748–58PubMedCrossRefGoogle Scholar
  51. 51.
    Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006; 45: 771–91PubMedCrossRefGoogle Scholar
  52. 52.
    Nakajima M, Terao T, Iwata N. Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: effects on hyperprolactinemia. Pharmacopsychiatry 2005; 38: 17–9PubMedCrossRefGoogle Scholar
  53. 53.
    Kinon MJ, Ahl J, Liu-Siefert H. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional anti-psychotics or risperidone to olanzapine. Psychoneuroendocrinology 2006; 31: 577–88PubMedCrossRefGoogle Scholar
  54. 54.
    Rego MD, Giller EL. Mania secondary to amantadine treatment of neuroleptic-induced hyperprolactinemia. J Clin Psychiatry 1989; 50: 143–4PubMedGoogle Scholar
  55. 55.
    Smith S. Neuroleptic-associated hyperprolactinemia: can it be treated with bromocriptine? J Reprod Med 1992; 37: 737–40PubMedGoogle Scholar
  56. 56.
    Bankowski BJ, Zacur HA. Dopamine agonist therapy for hyperprolactinemia. Clin Obstet Gynecol 2003; 46: 349–62PubMedCrossRefGoogle Scholar
  57. 57.
    Javaid MK, Holt RI. Understanding osteoporosis. J Psychopharmacol 2008; 22(2 Suppl.): 38–45PubMedCrossRefGoogle Scholar
  58. 58.
    Holt RI. A context for psychiatrists: medical causes and consequences of hyperprolactinemia. J Psychopharmacol 2002; 22(2 Suppl.): 28–37Google Scholar
  59. 59.
    Samllridge RC, Whorton NE, Burman KD, et al. Effects of exercise and physical fitness on the pituitary-thyroid axis and on prolactin secretion in male runners. Metabolism 1985; 34: 949–54CrossRefGoogle Scholar
  60. 60.
    Eskildsen PC, Kirkegaard CB. Influence of thyroid disorders on the dopaminergic regulation of prolactin, thyrotropin and growth hormone. J Endocrinol Invest 1985; 8: 427–31PubMedGoogle Scholar
  61. 61.
    Ellison DH, Berl T. Clinical practice: the syndrome of inappropriate antidiuresis. N Engl J Med 2007; 356: 2064–72PubMedCrossRefGoogle Scholar
  62. 62.
    Pimentel L. Medical complications of oncologic disease. Emerg Med Clin North Am 1993 May; 11: 407–19PubMedGoogle Scholar
  63. 63.
    Dundas B, Harris M, Narasimhan M. Psychogenic polydipsia review: etiology, differential, and treatment. Curr Psychiatry Rep 2007; 9: 236–41PubMedCrossRefGoogle Scholar
  64. 64.
    Ananth J, Lin KM. SIADH: a serious side effect of psychotropic drugs. Int J Psychiatr Med 1987; 16: 401–7CrossRefGoogle Scholar
  65. 65.
    Davison P, Wardrope J. Acute amitriptyline withdrawal and hyponatremia. Drug Saf 1993; 8: 78–80PubMedCrossRefGoogle Scholar
  66. 66.
    Gandelman MS. Review of carbamazepine-induced hyponatremia. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 211–33PubMedCrossRefGoogle Scholar
  67. 67.
    Rider JM, Mauger TF, Jameson JP. Water handling in patients receiving haloperidol decanoate. Ann Pharmacother 1995; 29: 663–6PubMedGoogle Scholar
  68. 68.
    Liu BA, Mittmann N, Knowles SR, et al. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: review of spontaneous reports. Can Med Assoc J 1996; 155: 519–27Google Scholar
  69. 69.
    Siegel A, Baldessarini RJ, Klepser MB, et al. Primary and drug-induced disorders of water homeostasis in psychiatric patients: principles of diagnosis and management. Harvard Rev Psychiatry 1998; 6: 190–200CrossRefGoogle Scholar
  70. 70.
    Kalantar-Zadeh K, Nguyen MK, Chang R, et al. Fatal hyponatremia in a young woman after ecstasy ingestion. Nat Clin Pract Nephrol 2006; 2: 283–8PubMedCrossRefGoogle Scholar
  71. 71.
    Mann K, Rossbach W, Muller MJ, et al. Noctournal hormone profiles in patients with schizophrenia treated with olanzapine. Psychoneuroendocrinology 2006; 31: 256–64PubMedCrossRefGoogle Scholar
  72. 72.
    Romero S, Pintor L, Serra M. Syndrome of inappropriate secretion of antidiuretic hormone due to citalopram and venlafaxine. Gen Hosp Psychiatry 2007; 29: 81–4PubMedCrossRefGoogle Scholar
  73. 73.
    Matsumura M, Yamaguchi M, Sato T. Severe hyponatremia in a patient treated with levomepromazine and carbamazepine [letter]. Intern Med 2001; 40: 459PubMedCrossRefGoogle Scholar
  74. 74.
    Atalay A, Turhan N, Aki OE. A challenging case of syndrome of inappropriate secretion of antidiuretic hormone in an elderly patient secondary to quetiapine. South Med J 2007; 100: 832–3PubMedCrossRefGoogle Scholar
  75. 75.
    Vucicevic Z, Degoricija V, Alfirevic Z, et al. Fatal hyponatremia and other metabolic disturbances associated with psychotropic drug polypharmacy. Int J Clin Pharmacol Ther 2007; 45: 289–92PubMedGoogle Scholar
  76. 76.
    Sarma S, Ward W, O’Brien J, et al. Severe hyponatremia associated with desmopressin nasal spray to treat clozapine-induced nocturnal enuresis. Aust NZ J Psychiatry 2005; 39: 949–50CrossRefGoogle Scholar
  77. 77.
    Weaver A, Dobson P. Nocturnal enuresis in children. J Fam Health Care 2007; 17: 159–61PubMedGoogle Scholar
  78. 78.
    Petersson I, Nilsson G, Hansson BG, et al. Water intoxication associated with non-steroidal anti-inflammatory drug therapy. Acta Med Scand 1987; 221: 221–3PubMedCrossRefGoogle Scholar
  79. 79.
    Mann SJ. The silent epidemic of thiazide-induced hyponatremia. J Clin Hypertens (Greenwich) 2008 Jun; 10(6): 477–84CrossRefGoogle Scholar
  80. 80.
    Ayus JC, Arieff AI. Chronic hyponatremic encephalopathy in postmenopausal women: association of therapies with morbidity and mortality. JAMA 1999; 281: 2299–304PubMedCrossRefGoogle Scholar
  81. 81.
    Fried LF, Palevsky PM. Hyponatremia and hypernatremia. Med Clin North Am 1997; 81: 585–609PubMedCrossRefGoogle Scholar
  82. 82.
    Lane RM. SSRIs and hyponatremia. Br J Clin Pract 1997; 51: 144–6PubMedGoogle Scholar
  83. 83.
    Bendz H, Aurell M. Drug-induced diabetes insipidus: incidence, prevention and management. Drug Saf 1999; 21: 449–56PubMedCrossRefGoogle Scholar
  84. 84.
    Sze L, Ulrich B, Brandle M. Severe hypernatremia due to nephrogenic diabetes insipidus: life-threatening side effect of chronic lithium therapy. Exp Clin Endocrinol Diabet 2006; 114: 596–8CrossRefGoogle Scholar
  85. 85.
    Hetmar O, Rafaelsen OJ. Lithium: long-term effects on the kidney. Acta Psychiatr Scand 1987; 76: 193–8PubMedCrossRefGoogle Scholar
  86. 86.
    Paw H, Slingo ME, Tinker M. Late onset nephrogenic diabetes insipidus following cessation of lithium therapy. Anaesth Intensive Care 2007; 35: 278–80PubMedGoogle Scholar
  87. 87.
    Raedler TJ, Wiedemann K. Lithium-induced nephropathies. Psychopharmacol Bull 2007; 40: 134–49PubMedGoogle Scholar
  88. 88.
    Bichet DG. Nephrogenic diabetes insipidus. Adv Chronic Kidney Dis 2006; 13: 96–104PubMedCrossRefGoogle Scholar
  89. 89.
    Livingston C, Rampes H. Lithium: review of its metabolic adverse effects. J Psychopharmacol 2006; 20: 347–55CrossRefGoogle Scholar
  90. 90.
    Henderson DC, Goff DC. Clozapine for polydipsia and hyponatremia in chronic schizophrenics. Biol Psychiatry 1994; 36: 768–70PubMedCrossRefGoogle Scholar
  91. 91.
    Spears NM, Leadbetter RA, Shutty Jr MS, et al. Treatment of polydipsia and hyponatremia in psychiatric patients: can clozapine be a new option? Neuropsychopharmacology 1995; 12: 133–8CrossRefGoogle Scholar
  92. 92.
    Canuso CM, Goldman MB. Clozapine restores water balance in schizophrenic patients with polydipsiahyponatremia syndrome. J Neuropsychiatry Clin Neurosci 1999; 11: 86–90PubMedGoogle Scholar
  93. 93.
    Adam P. Evaluation and management of diabetes insipidus. Am Fam Physician 1997; 55: 2146–53PubMedGoogle Scholar
  94. 94.
    Finch CK, Kelley KW, Williams RB. Treatment of lithiuminduced diabetes insipidus with amiloride. Pharmacotherapy 2003; 23: 546–50PubMedCrossRefGoogle Scholar
  95. 95.
    Bocchetta A, Loviselli A. Lithium treatment and thyroid abnormalities. Clin Pract Epidemol Ment Health 2006; 2: 23–8CrossRefGoogle Scholar
  96. 96.
    Ramschak-Schwartzer S, Radkohl W, Stiegler C, et al. Interaction between psychotropic drugs and thyroid hormone metabolism: overview. Acta Med Austriaca 2000; 27: 8–11CrossRefGoogle Scholar
  97. 97.
    Surks MI, Sievert R. Drugs and thyroid function. New Engl J Med 1995; 333: 1688–94PubMedCrossRefGoogle Scholar
  98. 98.
    Eiris-Punal J, Del Rio-Garma M, Del-Rio Garma MC, et al. Long term treatment of children with epilepsy with valproate or carbamazapine may cause subclinical hypothyroidism. Epilepsia 1999; 45: 1106–15Google Scholar
  99. 99.
    Benedetti MS, Whomsley R, Baltes E, et al. Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans: involvement of glucuronosyltransferease induction. Eur J Clin Pharmacol 2005 Dec; 61: 863–72PubMedCrossRefGoogle Scholar
  100. 100.
    Kelly DL, Conley RR. Thyroid function in treatmentresistant schizophrenia treated with quetiapine, risperidone, or fluphenazine. J Clin Psychiatry 2005; 66: 80–4PubMedCrossRefGoogle Scholar
  101. 101.
    McCracken JT, Hanna GL. Elevated thyroid indices in children and adolescents with obsessive-compulsive disorder: effects of clomipramine treatment. J Child Adolesc Psychopharmacol 2005; 15: 581–7PubMedCrossRefGoogle Scholar
  102. 102.
    Liappas J, Paparrigopoulos T, Mourikis I, et al. Hypothyroidism induced by quetiapine: a case report. J Clin Psychopharmacol 2006 Apr; 26: 208–9PubMedCrossRefGoogle Scholar
  103. 103.
    Lasser RA, Baldessarini RJ. Thyroid hormones in depressive disorders: reappraisal of clinical utility. Harvard Rev Psychiatry 1997; 4: 291–305CrossRefGoogle Scholar
  104. 104.
    Arafah BM. Increased need for thyroxine in women with hypothyroidism during estrogen therapy. New Engl J Med 2001; 344: 1743–9PubMedCrossRefGoogle Scholar
  105. 105.
    Kleiner J, Altshuler L, Hendrick V, et al. Lithium-induced subclinical hypothyroidism: review of the literature and guidelines for treatment. J Clin Psychiatry 1999; 60: 249–55PubMedCrossRefGoogle Scholar
  106. 106.
    Kahn DA, Sachs GS, Printz DJ, et al. Medication treatment guidelines of bipolar disorder 2000: a summary of the expert consensus guidelines. J Psychiatr Prac 2000; 6: 197–211CrossRefGoogle Scholar
  107. 107.
    Fagiolini A, Kupfer DJ, Scott J, et al. Hypothyroidism in patients with bipolar I disorder treated primarily with lithium. Epidemiol Psichiatr Soc 2006 Apr–Jun; 15(2): 123–7PubMedGoogle Scholar
  108. 108.
    Bunevicius R, Jakubonien N, Jurkevicius R, et al. Thyroxine versus thyroxine plus triiodothyronine in treatment of hypothyroidism after thyroidectomy for Graves’ disease. Endocrine 2002; 18: 129–33PubMedCrossRefGoogle Scholar
  109. 109.
    Siegmund W, Spieker K, Weike AI, et al. Replacement therapy with levothyroxine plus triiodothyronine is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism. Clin Endocrinol 2004; 60: 750–7CrossRefGoogle Scholar
  110. 110.
    Khandwala HM, Van Uum S. Reversible hypercalcemia and hyperparathyroidism associated with lithium therapy: case report and review of literature. Endocr Pract 2006; 12: 54–8PubMedGoogle Scholar
  111. 111.
    Suda DA, Schlickman PW, Perry PJ. Clinical dilemma of lithium-induced hyperparathyroidism in a treatmentresponsive patient. Ann Clin Psychiatry 2006; 18: 131–2PubMedCrossRefGoogle Scholar
  112. 112.
    Sloand JA, Shelly MA. Normalization of lithium-induced hypercalcemia and hyperparathyroidism with cinalcet hydrochloride. Am J Kidney Dis 2006; 48: 832–7PubMedCrossRefGoogle Scholar
  113. 113.
    Chiba Y, Satoh K, Ueda S, et al. Marked improvement of psychiatric symptoms after parathyroidectomy in elderly primary hyperparathyroidism. Endocrine J 2007; 54: 379–83CrossRefGoogle Scholar
  114. 114.
    Caksen H, Dulger H, Cesur Y, et al. Evaluation of thyroid and parathyroid functions in children receiving long-term carbamazepine therapy. Int J Neurosci 2003; 113: 1213–7PubMedCrossRefGoogle Scholar
  115. 115.
    Nicolaidou P, Georgouli H, Kotsalis H, et al. Effects of anticonvulsant therapy on vitamin-D status in children: prospective monitoring study. J Child Neurol 2006; 21: 205–9PubMedGoogle Scholar
  116. 116.
    Haney EM, Chan BK, Diem DL, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 2007; 167: 1246–51PubMedCrossRefGoogle Scholar
  117. 117.
    Goodman SB, Jiranek W, Petrow E, et al. Effects of medications on bone. J Am Acad Orthop Surg 2007; 15: 450–60PubMedGoogle Scholar
  118. 118.
    Halbreich U. Osteoporosis, schizophrenia and anti-psychotics: need for a comprehensive multifactorial evaluation. CNS Drugs 2007; 21: 641–57PubMedCrossRefGoogle Scholar
  119. 119.
    Laekeman G, Zwaenepoel L, Reyntens J, et al. Osteoporosis after combined use of a neuroleptic and antidepressants. Pharm World Sci 2008; 30: 613–6PubMedCrossRefGoogle Scholar
  120. 120.
    Petronijevic M, Petronijevic N, Ivkovic M, et al. Low bone mineral density and high bone metabolism turnover in premenopausal women with unipolar depression. Bone 2008; 42: 582–90PubMedCrossRefGoogle Scholar
  121. 121.
    Jayasinghe Y, Grover SR, Zacharin M. Current concepts in bone and reproductive health in adolescents with anorexia nervosa. BJOG 2008; 115: 304–15PubMedCrossRefGoogle Scholar
  122. 122.
    Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008; 83: 1032–45PubMedCrossRefGoogle Scholar
  123. 123.
    Stimmel GL, Gutierrez MA. Sexual dysfunction and psychotropic medications. CNS Spectr 2006; 11 Suppl. 9: 24–30Google Scholar
  124. 124.
    Joffe H, Hall JE, Cohen LS, et al. A putative relationship between valproic acid and polycystic ovarian syndrome: implications for treatment of women with seizure and bipolar disorders. Harvard Rev Psychiatry 2003; 11: 99–108Google Scholar
  125. 125.
    Joffe H, Cohen LS, Suppes T, et al. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry 2006; 59: 1078–86PubMedCrossRefGoogle Scholar
  126. 126.
    Joffe H, Cohen LS, Suppes T, et al. Longitudinal follow-up of reproductive and metabolic features of valproateassociated polycystic ovarian syndrome features. Biol Psychiatry 2006; 60: 1378–81PubMedCrossRefGoogle Scholar
  127. 127.
    Taylor MJ, Rudkin L, Hawton K. Strategies for managing antidepressant-induced sexual dysfunction: systematic review of randomized, controlled trials. J Affect Disord 2005; 88: 241–54PubMedCrossRefGoogle Scholar
  128. 128.
    Ozmenler NK, Karlidere T, Bozkurt A, et al. Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors. Hum Psychopharmacol 2008; 23: 321–6PubMedCrossRefGoogle Scholar
  129. 129.
    Balon R. SSRI-associated sexual dysfunction. Am J Psychiatry 2006; 163: 1504–9PubMedCrossRefGoogle Scholar
  130. 130.
    Jacobsen FM. Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 1992; 53: 119–22PubMedGoogle Scholar
  131. 131.
    Cicero AF, Piacente S, Plaza A, et al. Hexanic Maca extract improves rat sexual performance more effectively than methanolic and chloroformic Maca extracts. Andrologica 2002; 34: 177–9CrossRefGoogle Scholar
  132. 132.
    Yeh KY, Pu HF, Kaphle K, et al. Gingko biloba extract enhances male copulatory behavior and reduces serum prolactin levels in rats. Horm Behav 2007; 53: 225–31PubMedCrossRefGoogle Scholar
  133. 133.
    Auger RR, Goodman SH, Silber MH, et al. Risks of highdose stimulants in the treatment of disorders of excessive somnolence: case-control study. Sleep 2005; 28: 667–72PubMedGoogle Scholar
  134. 134.
    Baptista T, ElFakih Y, Uzcagetgui E, et al. Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 2008; 22: 477–95PubMedCrossRefGoogle Scholar
  135. 135.
    Hainer V, Kabrnova K, Aldhoon B, et al. Serotonin and norepinephrine reuptake inhibition and eating behavior. Ann NY Acad Sci 2006; 1083: 252–69PubMedCrossRefGoogle Scholar
  136. 136.
    Lader M. Pharmacotherapy of mood disorders and treatment discontinuation. Drugs 2007; 67: 1657–63PubMedCrossRefGoogle Scholar
  137. 137.
    Sussman N, Ginsberg DL, Bikoff J. Effects of nefazodone on body weight: pooled analysis of selective serotonin reuptake inhibitor- and impramine-controlled trials. J Clin Psychiatry 2001; 62: 256–60PubMedCrossRefGoogle Scholar
  138. 138.
    Hecht-Orzack M, Cole JO, Friedman L, et al. Weight changes with antidepressants: comparison of amitriptyline and trazodone. Neuropsychobiology 1986; 15 Suppl. 1: 28–30CrossRefGoogle Scholar
  139. 139.
    Baldessarini RJ. Chapter 17: drug therapy of depression and anxiety disorders. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman’s the pharmacological basis of therapeutics, 1 1th ed. New York: McGraw-Hill Press, 2005: 429–59Google Scholar
  140. 140.
    Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008; 28: 629–36PubMedCrossRefGoogle Scholar
  141. 141.
    Citrome LL. Increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents. Drugs Today 2004; 40: 445–64PubMedCrossRefGoogle Scholar
  142. 142.
    Harrison-Woolrych M, Garcia-Quiroga J, Ashton J, et al. Safety and usage of atypical antipsychotic medicines in children: nationwide prospective cohort study. Drug Saf 2007; 30: 569–79PubMedCrossRefGoogle Scholar
  143. 143.
    Logue DD, Gonzalez N, Heligman SD, et al. Hyperglycemia in a 7-year-old child treated with aripiprazole. Am J Psychiatry 2007; 164: 173–4PubMedCrossRefGoogle Scholar
  144. 144.
    Parent MM, Roy S, Sramek J, et al. Effect of molindone on weight change in hospitalized schizophrenic patients. Drug Intell Clin Pharm 1986; 20: 873–5PubMedGoogle Scholar
  145. 145.
    Goodnick PJ, Henry JH, Buki VM. Treatment of depression in patients with diabetes mellitus. J Clin Psychiatry 1995; 56: 128–36PubMedGoogle Scholar
  146. 146.
    Allison DB, Mentore JL, Heo M, et al. Antipsychoticinduced weight-gain: comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–96PubMedGoogle Scholar
  147. 147.
    Luef GJ, Lechleitner M, Bauer G, et al. Valproic acid modulates islet cell insulin secretion: possible mechanism of weight-gain in epilepsy patients. Epilepsy Res 2003; 55: 53–8PubMedCrossRefGoogle Scholar
  148. 148.
    Lagace DC, McLeod RS, Nachtigal MW. Valproic acid inhibits leptin secretion and reduces leptin messenger ribonucleic acid levels in adipocytes. Endocrinology 2004; 145: 5493–503PubMedCrossRefGoogle Scholar
  149. 149.
    Bowden CL, Calabrese JR, Ketter TA, et al. Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. Am J Psychiatry 2006; 163: 1199–201PubMedCrossRefGoogle Scholar
  150. 150.
    Aliyazicioglu R, Kural B, Colak M, et al. Treatment with lithium, alone or in combination with olanzapine, relieves oxidative stress but increases atherogenic lipids in bipolar disorder. Tohoku J Exp Med 2007; 213: 79–87PubMedCrossRefGoogle Scholar
  151. 151.
    Correll CU. Weight gain and metabolic effects of moodstabilizers and antipsychotics in pediatric bipolar disorder: systematic review and pooled analysis of short term trials. J Am Acad Child Adolesc Psychiatry 2007; 46: 687–700PubMedCrossRefGoogle Scholar
  152. 152.
    Correll CU. Balancing efficacy and safety in treatment with antipsychotics. CNS Spectr 2007; 12 Suppl. 17: 12–20Google Scholar
  153. 153.
    Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, et al. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population. Schizophrenia Res 2008; 99: 13–22CrossRefGoogle Scholar
  154. 154.
    Strassnig M, Miewald J, Keshavan M, et al. Weight-gain in newly diagnosed first-episode psychosis patients and healthy comparison: one year analysis. Schizophrenia Res 2007; 93: 90–8CrossRefGoogle Scholar
  155. 155.
    Tohen M, Bowden CL, Smulevich AB, et al. Olanzapine plus carbamazepine vs. carbamazepine alone in treating manic episodes. Br J Psychiatry 2008; 192: 135–43CrossRefGoogle Scholar
  156. 156.
    Torrent C, Amann B, Sánchez-Moreno J, et al. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr Scand 2008; 118: 4–18PubMedCrossRefGoogle Scholar
  157. 157.
    Kim JY, Lee HW. Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy. Epilepsia 2007; 48: 1366–70PubMedCrossRefGoogle Scholar
  158. 158.
    Dunner DL. Safety and tolerability of emerging pharmacological treatments for bipolar disorder. Bipolar Disord 2005; 7: 307–25PubMedCrossRefGoogle Scholar
  159. 159.
    Fava M. Weight-gain and antidepressants. J Clin Psychiatry 2000; 61 Suppl. 11: 37–41Google Scholar
  160. 160.
    Lakka HM, Laaksonen DE, Lakka TA, et al. Metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709–16PubMedCrossRefGoogle Scholar
  161. 161.
    Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of metabolic syndrome: American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735–52PubMedCrossRefGoogle Scholar
  162. 162.
    Hardy TA, Marquez E, Kryzhanovskaya L, et al. Crosssectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics. J Clin Psychopharmacol 2006; 26: 405–8PubMedCrossRefGoogle Scholar
  163. 163.
    Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007; 68 Suppl. 4: 8–13Google Scholar
  164. 164.
    McElroy SL, Kotwal R, Malhotra S, et al. Are mood disorders and obesity related? Review for the mental health professional. J Clin Psychiatry 2004; 65: 634–51PubMedCrossRefGoogle Scholar
  165. 165.
    Evans DL, Charney DS, Lewis L, et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 2005; 58: 175–89PubMedCrossRefGoogle Scholar
  166. 166.
    Holt RI, Bushe C, Citrome L. Diabetes and schizophrenia 2005: are we any closer to understanding the link? J Psychopharmacol 2005; 19Suppl. 6: 56–65PubMedCrossRefGoogle Scholar
  167. 167.
    Amamoto T, Kumai T, Nakaya S, et al. The elucidation of the mechanism of weight gain and glucose tolerance abnormalities induced by chlorpromazine. J Pharmacol Sci 2006; 102: 213–9PubMedCrossRefGoogle Scholar
  168. 168.
    Ellingrod VL, Miller D, Taylor SF, et al. Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophrenia Res 2008; 98: 47–54CrossRefGoogle Scholar
  169. 169.
    Atmaca M, Kuloglu M, Tezcan E, et al. Serum leptin and cholesterol levels in schizophrenic patients with and without suicide attempts. Acta Psychiatr Scand 2003; 108: 208–14PubMedCrossRefGoogle Scholar
  170. 170.
    Casey DE. Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65 Suppl. 18: 27–35Google Scholar
  171. 171.
    Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: comprehensive review. Schizophrenia Res 2004; 70: 1–17CrossRefGoogle Scholar
  172. 172.
    Tarricone I, Casoria M, Gozzi BF, et al. Metabolic risk factor profile associated with use of second generation antipsychotics: cross sectional study in a community mental health center. BMC Psychiatry 2006; 6: 11–9PubMedCrossRefGoogle Scholar
  173. 173.
    De Leon J, Susce MT, Johnson M, et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophrenia Res 2007; 92: 95–102CrossRefGoogle Scholar
  174. 174.
    Henderson DC. Clozapine: diabetes mellitus, weight-gain, and lipid abnormalities. J Clin Psychiatry 2001; 62 Suppl. 23: 39–44Google Scholar
  175. 175.
    Wirshing DA, Boyd JA, Meng LR, et al. Effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002; 63: 856–65PubMedCrossRefGoogle Scholar
  176. 176.
    Melkersson KI, Dahl ML. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology 2003; 170: 157–66PubMedCrossRefGoogle Scholar
  177. 177.
    Markham-Abedi C, de Leon J. Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: case report. J Clin Psychiatry 2006; 67: 1473–4PubMedCrossRefGoogle Scholar
  178. 178.
    Procyshyn RM, Wasan KM, Thornton AE, et al. Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J Psychiatry Neurosci 2007; 32: 331–8PubMedGoogle Scholar
  179. 179.
    Wu RR, Zhao JP, Zhai JG, et al. Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. J Clin Psychopharmacol 2007; 27: 374–9PubMedCrossRefGoogle Scholar
  180. 180.
    Fraguas D, Merchán-Naranjo J, Laita P, et al. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry 2008; 69: 1166–75PubMedCrossRefGoogle Scholar
  181. 181.
    Rachenzauner M, Haberlandt E, Scholl Burgi S, et al. Effect of valproic acid treatment on body composition, leptin and the soluble leptin receptor in epileptic children. Epilepsy Res 2008; 80: 142–9CrossRefGoogle Scholar
  182. 182.
    Selikson S, Damus K, Hamerman DJ. Risk factors associated with immobility. Am Geriatr Soc 1988; 36: 707–12Google Scholar
  183. 183.
    Whyte EM, Drayer RA, Soreca I, et al. Medical burden in late-life bipolar and major depressive disorders. Am J Geriatr Psychiatry 2008; 16: 194–200PubMedCrossRefGoogle Scholar
  184. 184.
    Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008; 13: 27–35PubMedCrossRefGoogle Scholar
  185. 185.
    Aydin K, Serdaroglu A, Okuyaz C, et al. Serum insulin, leptin and neuropeptide y levels in epileptic children treated with valproate. J Child Neurol 2005; 20: 848–51PubMedCrossRefGoogle Scholar
  186. 186.
    Haupt DW, Luber A, Maeda J, et al. Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmacology 2005; 30: 184–91PubMedCrossRefGoogle Scholar
  187. 187.
    Baptista T, Dávila A, El Fakih Y, et al. Similar frequency of abnormal correlation between serum leptin levels and BMI before and after olanzapine treatment in schizophrenia. Int Clin Psychopharmacol 2007; 22: 205–11PubMedCrossRefGoogle Scholar
  188. 188.
    Baptista T, Sandia I, Lacruz A, et al. Insulin counterregulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. Int Clin Psychopharmacol 2007; 22: 69–76PubMedCrossRefGoogle Scholar
  189. 189.
    Hamed SA, Fida NM, Hamed EA. States of serum leptin and insulin in children with epilepsy: risk predictors of weight-gain. Eur J Paediatr Neurol 2009; 13: 261–8PubMedCrossRefGoogle Scholar
  190. 190.
    Mohs ME, Watson RR, Leonard-Green T. Nutritional effects of marijuana, heroin, cocaine, and nicotine. J Am Diet Assoc 1990; 90: 1261–7PubMedGoogle Scholar
  191. 191.
    Lynch ME, Young J, Clark AJ. Case series of patients using medical marihuana for management of chronic pain under Canadian Marihuana Medical Access Regulations. J Pain Symp Manage 2006; 32: 497–501CrossRefGoogle Scholar
  192. 192.
    Berkey CS, Rockett HR, Colditz GA. Weight-gain in older adolescent females: the internet, sleep, coffee, and alcohol. J Pediatr 2008; 153: 635–9PubMedCrossRefGoogle Scholar
  193. 193.
    Han DH, Bolo N, Daniels MA, et al. Craving for alcohol and food during treatment for alcohol dependence: modulation by T allele of 1519T-C GABA-A-a 6. Alcohol Clin Exp Res 2008; 32: 1593–9PubMedCrossRefGoogle Scholar
  194. 194.
    Le-Niculescu H, McFarland MJ, Ogden CA, et al. Phenomic, convergent functional genomic, and biomarker studies in a stress-reactive genetic animal model of bipolar disorder and co-morbid alcoholism. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 134–66PubMedCrossRefGoogle Scholar
  195. 195.
    Rathbone J, Variend H, Mehta H. Cannabis and schizophrenia. Cochrane Database Syst Rev 2008 Jul 16: (3) CD004837Google Scholar
  196. 196.
    Zink M, Mase E, Dressing H. Combination of ziprasidone and clozapine in treatment-resistant schizophrenia. Hum Psychopharmacol 2004; 19: 271–3PubMedCrossRefGoogle Scholar
  197. 197.
    Garman PM, Ried LD, Bengston MA, et al. Effect on lipid profiles of switching from olanzapine to another secondgeneration antipsychotic agent in veterans with schizophrenia. J Am Pharm Assoc 2007; 47: 373–8CrossRefGoogle Scholar
  198. 198.
    Mitsonis CI, Dimopoulos NP, Mitropoulos PA, et al. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 373–7PubMedCrossRefGoogle Scholar
  199. 199.
    Spurling RD, Lamberti JS, Olsen D, et al. Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: retrospective chart review. J Clin Psychiatry 2007; 68: 406–9PubMedCrossRefGoogle Scholar
  200. 200.
    Kontos N, Freudenreich O, Querques J. Using a medical model with psychotic patients. Am J Psychiatry 2006; 163: 1646–7PubMedCrossRefGoogle Scholar
  201. 201.
    Chen CH, Chiu CC, Huang MC, et al. Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 2007; 32: 925–31PubMedCrossRefGoogle Scholar
  202. 202.
    Goff DC. Integrating general health care in private community psychiatry practice. J Clin Psychiatry 2007; 68 Suppl. 4: 49–54Google Scholar
  203. 203.
    Gadde KM, Parker CB, Maner LG, et al. Bupropion for weight loss: investigation of efficacy and tolerability in overweight and obese women. Obesity Res 2001; 9: 544–51CrossRefGoogle Scholar
  204. 204.
    Gadde KM, Zhang W, Foust MS. Bupropion treatment of olanzapine-associated weight gain: open-label, prospective trial. J Clin Psychopharmacol 2006; 26: 409–13PubMedCrossRefGoogle Scholar
  205. 205.
    Bray GA. Medical therapy for obesity: current status and future hopes. Med Clin North Am 2007; 91: 1225–53PubMedCrossRefGoogle Scholar
  206. 206.
    Wooltorton E. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ 2002; 166: 1307–8PubMedGoogle Scholar
  207. 207.
    Henderson DC, Copeland PM, Daley TB, et al. Doubleblind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 2005; 162: 954–62PubMedCrossRefGoogle Scholar
  208. 208.
    Daniels SR, Long B, Crow S, et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study. Pediatrics 2007; 120: 147–57CrossRefGoogle Scholar
  209. 209.
    Henderson DC, Fan X, Copeland PM, et al. Double-blind, placebo-controlled trial of sibutramine for clozapineassociated weight gain. Acta Psychiatr Scand 2007; 115: 101–5PubMedCrossRefGoogle Scholar
  210. 210.
    Florentin M, Liberopoulos EN, Elisaf MS. Sibutramineassociated adverse effects: practical guide for its safe use. Obesity Rev 2007; 62: 88–96Google Scholar
  211. 211.
    Rubio MA, Gargallo M, Isabel Millán A, et al. Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant. Pub Health Nutr 2007; 10: 1200–5CrossRefGoogle Scholar
  212. 212.
    Cordeiro Q, Vallada H. Sibutramine-induced mania episode in a bipolar patient. Int J Neuropsychopharmacol 2002; 5: 283–4PubMedCrossRefGoogle Scholar
  213. 213.
    Litvan L, Alcoverro-Fortuny O. Sibutramine and psychosis. J Clin Psychopharmacol 2007; 27: 726–7PubMedCrossRefGoogle Scholar
  214. 214.
    Lee J, Teoh T, Lee TS. Catatonia and psychosis associated with sibutramine: case report and pathophysiologic correlation. J Psychosom Res 2008; 64: 107–9PubMedCrossRefGoogle Scholar
  215. 215.
    Trakas K, Shear NH. Serotonin syndrome risk with anti-obesity drug [letter]. Can J Clin Pharmacol 2000; 7: 216PubMedGoogle Scholar
  216. 216.
    Baptista T, Rangel N, Fernandez V, et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: multicentric, double-blind, placebo-controlled trial. Schizophrenia Res 2007; 93: 99–108CrossRefGoogle Scholar
  217. 217.
    Toplak H, Hamann A, Moore R, et al. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type-2 diabetes: randomized, double-blind, placebo-controlled study. Int J Obes 2007; 31: 138–46CrossRefGoogle Scholar
  218. 218.
    Wu RR, Zhao JP, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weightgain: randomized controlled trial. JAMA 2008; 299: 185–93PubMedCrossRefGoogle Scholar
  219. 219.
    Chengappa RKN, Schwarzman LK, Hulihan JF, et al.; Janssen Study-168 Investigators. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: randomized, placebo-controlled trial. J Clin Psychiatry 2006; 67: 1698–706CrossRefGoogle Scholar
  220. 220.
    Claudino AM, de Oliveira IR, Appolinario JC, et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in bingeeating disorders. J Clin Psychiatry 2007; 68: 1324–32PubMedCrossRefGoogle Scholar
  221. 221.
    McElroy SL, Frye MA, Altschuler LL, et al. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight-gain in overweight or obese patients with bipolar disorders. Bipolar Disord 2007; 9: 426–34PubMedCrossRefGoogle Scholar
  222. 222.
    Tramontina S, Zeni CP, Pheula G, et al. Topiramate in adolescents with juvenile bipolar disorder presenting with weight gain due to atypical antipsychotics or mood stabilizers: an open clinical trial. J Child Adolesc Psychopharmacol 2007; 17: 129–34PubMedCrossRefGoogle Scholar
  223. 223.
    Gualtieri CT, Johnson LG. Cognitive neurocognitive effects of five psychotropic anticonvulsants and lithium. MedGenMed 2006; 8: 46–7PubMedGoogle Scholar
  224. 224.
    Schrooyen M. Acute glaucoma originating from medication. Bull Soc Belge Ophtalmol 2007; 304: 125–31PubMedGoogle Scholar
  225. 225.
    Gadde KM, Yonish GM, Foust MS, et al. Combination therapy of zonisamide and bupropion for weight reduction in obese women: preliminary, randomized, openlabel study. J Clin Psychiatry 2007; 68: 1226–9PubMedCrossRefGoogle Scholar
  226. 226.
    Woo J, Sea MM, Tong P, et al. Effectiveness of a lifestyle modification programme in weight maintenance in obese subjects after cessation of treatment with orlistat. J Eval Clin Pract 2007; 13: 853–9PubMedGoogle Scholar
  227. 227.
    Joffe G, Takala P, Tchoukhine E, et al. Orlistat in clozapine-or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebocontrolled trial. J Clin Psychiatry 2008; 69: 706–11PubMedCrossRefGoogle Scholar
  228. 228.
    Werneke U, Taylor D, Sanders TA. Options for pharmacological management of obesity in patients treated with atypical antipsychotics. Int Clin Psychopharmacol 2002; 17: 145–60PubMedCrossRefGoogle Scholar
  229. 229.
    Scheen AJ. Cannabinoid-1 receptor antagonists in type-2 diabetes. Best Pract Res Clin Endocrinol Metab 2007; 21: 535–53PubMedCrossRefGoogle Scholar
  230. 230.
    Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a metaanalysis of randomized trials. Lancet 2007; 370: 1671–2CrossRefGoogle Scholar
  231. 231.
    Vemuri VK, Janero DR, Makriyannis A. Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. Physiol Behav 2008; 93: 671–86PubMedCrossRefGoogle Scholar
  232. 232.
    Gracious BL, Krysiak TE, Youngstrom EA. Amantadine treatment of psychotropic-induced weight-gain in children and adolescents: case series. J Child Adolesc Psychopharmacol 2002; 1: 249–57CrossRefGoogle Scholar
  233. 233.
    Graham KA, Gu H, Lieberman JA, et al. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry 2005; 162: 1744–6PubMedCrossRefGoogle Scholar
  234. 234.
    Henderson DC, Louie PM, Koul P, et al. Modafinilassociated weight loss in a clozapine-treated schizoaffective disorder patient. Ann Clin Psychiatry 2005; 17: 95–7PubMedCrossRefGoogle Scholar
  235. 235.
    Makris AP, Rush CR, Frederich RC, et al. Wakepromoting agents with different mechanisms of action: comparison of effects of modafinil and amphetamine on food intake and cardiovascular activi. Appetite 2004; 42: 185–95PubMedCrossRefGoogle Scholar
  236. 236.
    Hermanussen M, Tresguerres JA. A new anti-obesity drug treatment: first clinical evidence that, antagonizing glutamate-gated Ca2+ ion channels with memantine normalizes binge-eating disorders. Econ Hum Biol 2005; 3: 329–37PubMedCrossRefGoogle Scholar
  237. 237.
    Schaefer M, Leopold K, Hinzpeter A, et al. Memantineassociated reversal of clozapine-induced weight gain. Pharmacopsychiatry 2007; 40: 149–51PubMedCrossRefGoogle Scholar
  238. 238.
    American Diabetes Association (ADA), American Psychiatric Association (APA), American Association of Clinical Endocrinologists (AACE), North American Association for the Study of Obesity (NAASO). Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004; 27: 596–691CrossRefGoogle Scholar
  239. 239.
    Su KP, Wu PL, Pariante CM. A crossover study on lipid and weight changes associated with olanzapine and risperidone. Psychopharmacology 2005; 183: 383–6PubMedCrossRefGoogle Scholar
  240. 240.
    Weiden PJ. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight-gain and dyslipidemia. J Clin Psychiatry 2007; 68 Suppl. 4: 34–9Google Scholar
  241. 241.
    Van Winkel R, De Hert M, Wampers M, et al. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2008; 69: 472–9PubMedCrossRefGoogle Scholar
  242. 242.
    Ojala K, Repo-Tiihonen E, Tiihonen J, et al. Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents. J Psychopharmacol 2008; 22: 33–8PubMedCrossRefGoogle Scholar
  243. 243.
    Weiss AP, Henderson DC, Weilburg JB, et al. Treatment of cardiac risk factors in patients with schizophrenia and diabetes. Psychiatr Serv 2006; 57: 1145–52PubMedCrossRefGoogle Scholar
  244. 244.
    Poulin MJ, Chaput JP, Simard V, et al. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise program. Aust NZ J Psychiatry 2007; 41: 980–9CrossRefGoogle Scholar
  245. 245.
    Henderson DC, Cagliero E, Copeland PM, et al. Elevated hemoglobin-A1C as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. J Clin Psychiatry 2007; 68: 533–41PubMedCrossRefGoogle Scholar
  246. 246.
    Faulkner G, Cohn TA. Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications. Can J Psychiatry 2006; 51: 502–11PubMedGoogle Scholar
  247. 247.
    Greenberg I, Chan S, Blackburn GL. Nonpharmacologic and pharmacologic management of weight gain. J Clin Psychiatry 1999; 60 Suppl. 21: 31–6Google Scholar
  248. 248.
    Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 2007 Jan 24; (1): CD005148Google Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Chaya G. Bhuvaneswar
    • 1
  • Ross J. Baldessarini
    • 2
    • 3
  • Veronica L. Harsh
    • 4
  • Jonathan E. Alpert
    • 2
  1. 1.Department of PsychiatryUniversity of PennsylvaniaPhiladelphiaUSA
  2. 2.Departments of PsychiatryHarvard Medical School and Massachusetts General HospitalBostonUSA
  3. 3.McLean HospitalBelmontUSA
  4. 4.Behavioral Endocrinology BranchNational Institute of Mental HealthBethesdaUSA

Personalised recommendations